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Abstract (250 words) 
 
Objective(s): To determine the proportion of individuals linking to HIV-care with advanced 
HIV-disease (CD4 ≤200 cells/µL) in the Botswana Combination Prevention Project, describe 
the characteristics of these individuals, and examine treatment outcomes. 
Design: A sub-analysis of a cluster-randomized HIV-prevention trial. HIV status was assessed 
in 16-64-year-olds through home and mobile testing. All HIV-positive persons not on 
antiretroviral-therapy (ART) were referred to local Ministry of Health and Wellness clinics for 
treatment. 
Methods: Analysis was restricted to the 15 intervention clusters. The proportion of individuals 
with advanced HIV disease was determined; associations between advanced HIV disease and 
sex and age explored; and rates of viral suppression determined at 1-year. Mortality and 
retention in care were compared between CD4 strata (CD4 ≤200 cells/µL vs. >200 cells/µL). 
Results: Overall, 17.2% (430/2,499; 95% confidence interval [CI] 15.7-18.8%) of study 
participants had advanced HIV disease (CD4 ≤200 cells/µL) at time of clinic linkage. Men were 
significantly more likely to present with CD4 ≤200 cells/µL than women (23.7% versus 13.4%, 
adjusted odds ratio [aOR] 1.9, 95% CI 1.5-2.3). The risk of advanced HIV disease increased 
with increasing age (aOR 2.2, 95% CI 1.4-3.2  >35 years versus <25 years). Patients with  CD4 
≤200 cells/µL had significantly higher rates of attrition from care during follow-up (hazards 
ratio 1.47, 95% CI 1.1-2.1).  
Conclusions: Advanced HIV disease due to late presentation to or disengagement from ART 
care remains common in the Treat All era in Botswana, calling for innovative testing, linkage, 
and treatment strategies to engage and retain harder-to-reach populations in care.   
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Introduction 
Botswana was one of the first African countries to introduce a national antiretroviral therapy 
(ART) treatment programme, rolling out free ART to clinically-eligible HIV-positive citizens in 
2002. In June 2016, following updated World Health Organization (WHO) guidance[1], 
universal HIV treatment (“Treat All”) was introduced, with population-level data suggesting 
that Botswana was close to achieving the Joint United Nations Programme on HIV/AIDS 90-
90-90 targets[2, 3]. Despite these notable successes, Botswana still has one of the highest HIV-
prevalence rates globally with an estimated 20.3% of adults living with HIV in 2018[4], and 
continues to have high estimated HIV incidence rates of 1% or more[5, 6]. Data also show a 
considerable ongoing burden of HIV-related morbidity and mortality, including high rates of 
tuberculosis[7], cryptococcal meningitis[8], and HIV-associated malignancies[9]. Both late 
initiation of ART and default or disengagement from HIV care are likely to contribute to both 
the high rates of onward HIV-transmission at a population level[10], and the prevalence of 
advanced HIV disease (CD4 cell counts ≤200 cells/µL or WHO stage 3 or 4 disease)[11], HIV-
related morbidity, and mortality[12]. Botswana, in common with most African countries, has 
adopted a public health approach to ART provision which has understandably focussed on 
initiating as many individuals as possible on ART. This has been particularly notable since the 
switch to universal treatment, with considerable resources allocated to finding and initiating 
newly eligible individuals, often with high CD4 counts. A potential unintended consequence 
of this may be a failure to appropriately provide the more intensive management needed to 
effectively engage and retain vulnerable individuals who may then present with advanced HIV 
disease. Understanding which patient populations are at risk of developing advanced HIV 
disease is important to enable implementation of strategies to appropriately identify and 
engage them in HIV treatment services. 
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Using data from the Botswana Combination Prevention Project (BCPP)[6], a large community-
based HIV prevention trial, we determined the proportion of individuals linking to HIV-
treatment services with advanced HIV-disease in Botswana, describe the characteristics of 




Study design and participants. BCPP was a cluster-randomized HIV-prevention trial 
evaluating the impact of prevention interventions on population-level HIV incidence in 15 
rural or peri-urban community clusters, with 15 matched control community clusters[3, 6]. We 
conducted a cross-sectional analysis using baseline BCPP data to examine the prevalence and 
correlates of advanced HIV disease, an analysed prospective cohort data to determine clinical 
outcomes in patients according to advanced HIV-disease status. BCPP study interventions 
took place between October 2013 and March 2018.  HIV status was assessed in all 16-64-year-
old community residents identified through BCPP testing activities. All newly-identified and 
known HIV-positive persons not on ART were referred to their local Ministry of Health and 
Wellness (MoHW) community clinic for ART initiation. ART was provided free of charge to 
citizens and their spouses. Prior to the introduction of “Treat All” and rapid ART initiation, 
from 2013 to June 2016, all HIV-positive individuals not on ART had a point-of-care (POC) CD4 
count performed by trained HIV counsellors (PIMA™ CD4, Alere, Inc. Waltham, MA, USA) at 
the initial community intake contact. During this period ART was initiated (i) at CD4 <350 
cells/µL or WHO clinical stage 3 or 4; or (ii) if they met the BCPP expanded ART eligibility 
criteria of CD4 <500 cells/µL or CD4 >500 cells/µL and viral load (VL) > 10,000 copies/mL. First-
line therapy during this period consisted of tenofovir, emtricitabine, and efavirenz as a single 
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fixed-dose combination tablet. From June 2016, “Treat All” was implemented and all HIV-
positive persons were eligible and referred for ART regardless of CD4 count or disease stage. 
Baseline VL testing and POC CD4 testing were discontinued in June 2016; routine CD4 testing 
was still performed at the initial clinic visit using the BD FACSCalibur (Beckton Dickinson, Inc.), 
although ART was initiated prior to receiving CD4 (or safety lab) results. First-line ART also 
changed in June 2016 to tenofovir and emtricitabine as a combination tablet, plus 
dolutegravir. Patients were followed-up according to Botswana national guidelines[13]. Deaths 
were ascertained from clinic records and the electronic medical records system. Efforts were 
made to trace individuals lost to follow-up and to encourage them to return to clinic through 
telephone calls or home visits. Individuals who received ART outside of standard of care (prior 
to June 2016) provided informed consent, and waiver of consent was obtained for all 
others.The study was approved by the United States Centers for Disease Control and 
Prevention (CDC) Institutional Review Board (Protocol #6475) and the Botswana Health 
Research and Development Committee, and prospectively registered at ClinicalTrials.gov 
(NCT01965470).  
Statistical analysis. The primary objectives of the analysis were to determine the proportion 
of HIV-positive individuals linking to clinics for HIV care with advanced HIV disease, describe 
factors associated with advanced HIV disease, and assess clinical outcomes according to 
baseline CD4 count (defined as the CD4 count closest to time of clinic linkage, no more than 
90 days prior to or 30 days post linkage). The proportions of individuals presenting with 
advanced HIV disease in the pre-Treat All and Treat All periods were compared. This analysis 
was restricted to study participants in the 15 intervention clusters who linked to care at a 
MoHW facility in the intervention community. Baseline characteristics of the study 
participants were described, and the overall proportion of individuals with advanced HIV 
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disease (defined as a baseline CD4 cell count ≤200 cells/µL as staging data were not available 
for all participants) determined. Associations between advanced HIV disease and sex, age, 
prior knowledge of HIV status (determined through self-report or evidence of prior HIV-
positive diagnosis in the electronic medical records system), and HIV testing location were 
explored in stratified analyses, and quantified using univariable logistic regression models and 
adjusted multivariable models including age and sex. The sensitivity and specificity of WHO 
clinical staging for identification of advanced HIV disease were calculated in those with WHO 
staging data. Rates of viral suppression (defined as a plasma VL <400 copies/mL) were 
determined at 1-year post-ART initiation in individuals eligible for ART initiation. The 
proportions of individuals who had died within one year of linkage and at completion of study 
follow-up were reported, and overall retention in care presented using Kaplan-Meier curves 
and compared between CD4 strata (CD4 ≤200 cells/µL vs. >200 cells/µL) using a Cox 
proportional hazards regression model. All analyses accounted for clustering by community, 
with hierarchical mixed effects regression models incorporating a random effects term for 
community, and robust 95% confidence intervals (95%CIs) reported throughout. P-values for 
comparisons of medians were derived from ranked testing (F-testing) of Somers’ D parameter 
estimates accounting for clustering by site (comparable to a Kruskal-Wallis test). Patients 
were considered lost to follow-up if they had not attended any HIV-related clinic activity 
(clinic appointment, blood draw, or ART refill) within 180 days of data censoring on 28th June 
2018.  Data were analysed using Stata version 14 (StataCorp, College Station, TX, USA). P-




Between October 2013 and March 2018 2,908 HIV-positive community residents who were 
not taking ART were identified and linked for ART at a BCPP intervention community clinic, of 
whom 2,499 (85.9%) had a documented baseline CD4 cell count and were included in this 
analysis (details of the full BCPP cohort are given in supplementary tables 1 and 2). Of the 
2,499 baseline CD4 cell counts performed, 1,872 (74.9%) were measured using the PIMA CD4 
(Alere, Inc.) and 627 (25.1%) using the BD FACSCalibur (Beckton Dickinson, Inc.). Baseline 
characteristics of participants are shown in Table 1. Overall, 17.2% (430/2,499; 95%CI 15.7-
18.8%) of study participants had advanced HIV disease defined as baseline CD4 count ≤200 
cells/µL at the time of clinic linkage (Figure 1a). Men were significantly more likely than 
women to present with CD4 ≤200 cells/µL (23.7% versus 13.4%, adjusted odds ratio (aOR) 1.9, 
95%CI 1.5-2.3). The risk of advanced HIV disease increased with advancing age (9.1% of those 
<25 years, 15.0% of those aged 25-34 years, and 20.4% of those >35 years; aOR relative to 
the <25 years category of 1.5 (95%CI 1.0-2.4) and 2.2 (95%CI 1.4-3.2) respectively)(Figure 1b). 
Other factors found to be significantly associated with higher rates of advanced HIV disease 
were a new (rather than previously known) HIV diagnosis (aOR 1.3, 95%CI 1.0-1.6); HIV-testing 
through mobile rather than home-based contact (aOR 1.3, 95%CI 1.0-1.6); and being widowed 
or divorced (aOR 2.6, 95%CI 1.6-4.3) (Table 1.b). There was no decline in the proportion of 
individuals linking to care with CD4 ≤200 cells/µL over time; in fact, the proportion increased 
from 15.5% (315/2,034; 95%CI 13.4-17.9%) prior to introduction of Treat All, to 24.7% 
(115/465; 95%CI 20.4-29.6%) during Treat All, p<0.001. One hundred and thirty of the 2,499 
participants (5.2%, 95% CI 4.3-6.3%) had very advanced HIV disease (CD4 count ≤100 cells/µL); 
presentation with very advanced disease was significantly associated with male sex and older 
age (Table 2). 
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WHO clinical staging were available for 1,787/2,499 study participants. Clinical staging using 
WHO stage 3 or 4 disease had a sensitivity of 6.0% (95%CI 3.6-9.3%) and specificity of 96.8% 
(95%CI 95.8-97.7%) for detecting CD4 counts ≤200 cells/µL, giving a 27.7% positive predictive 
value (95%CI 17.3-40.2%) and 83.6% negative predictive value (81.8%-85.3%). Eighty-two 
percent (246/300) of individuals with CD4 ≤200 cells/µL and staging data available had WHO 
stage 1 disease. 
At the time of linkage 2,193/2,499 individuals were eligible for ART initiation according to 
study eligibility criteria. ART was initiated in 97.2% (418/430) of individuals with CD4 ≤200 
cells/µL, and 96.4% (1,699/1,763) of eligible individuals with CD4 >200 cells/µL, p=0.40. 
Retention in care following ART initiation, stratified by CD4 count (≤200 vs. >200), is shown in 
Figure 1c. Patients with  CD4 ≤200 cells/µL had significantly higher rates of attrition from care 
during study follow-up (hazards ratio 1.47, 95%CI 1.1-2.1). Rates of attrition from care in 
patients with CD4 ≤200 cells/µL were similar in individuals with new and previously-known 
HIV diagnosis (hazards ratio 1.1, 95%CI 0.6-2.0; Figure 2). Documented mortality was 2.1% 
(9/430) in the CD4 ≤200 cells/µL group compared to 0.7% (13/1763) in those with CD4 >200 
cells/µL within one year of clinic linkage, and 4.9% (21/430) versus 1.7% (30/1763) at the end 
of study follow-up (p<0.001). Overall 86.6% (95%CI 81.8-90.2%) of all individuals linking to 
care with a CD4 ≤200 cells/µL were in care, on ART, and had a suppressed VL after one year, 
compared to 92.1% (95%CI 89.5-94.0%) of those with baseline CD4 >200 cells/µL, p<0.001. 
 
Discussion 
Advanced HIV disease was common among adults presenting for HIV care in rural and peri-
urban Botswana between 2013 and 2018. Despite a well-established ART programme with 
high levels of population coverage[3], almost one in seven women, and one in four men had 
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CD4 cell counts ≤200 cells/µL at the time of clinic linkage. The proportion of individuals linking 
to care with advanced HIV disease increased with age in both men and women, with the 
highest rates in those ≥35 years of age. In keeping with prior studies[12, 14], treatment 
outcomes were worse in individuals initiating ART with advanced HIV disease compared to 
those initiating at higher CD4 counts, although our data show that relatively high levels of 
retention in care and viral suppression can be achieved in this patient group with appropriate 
management. 
The ongoing burden of advanced HIV disease seen in Botswana in the Treat All era is 
consistent with data from South Africa[15-18], where a nationwide laboratory cohort estimated 
that 32.9% adults had advanced HIV disease at presentation, and 16.8% had very advanced 
HIV disease (CD4 <100 cells/µL) in 2016[15]. Subsequent data suggest that these figures have 
remained stable in 2017-2018 following the introduction of Treat All[17]. Notably, the 
proportion of advanced HIV disease in our cohort may underestimate the true burden of 
advanced HIV disease in Botswana as our study was limited to rural and peri-urban areas, and 
the population under study were exposed to widespread HIV testing interventions in the 
community and intensive efforts to improve linkage to care, perhaps leading to a higher 
proportion of patients being identified and initiated on ART while still in early stages of 
disease. This is supported by recent data from Gaborone (Botswana’s capital city) showing 
that 24.8% of 14,423 individuals undergoing baseline CD4 testing between 2015-2017 had 
CD4 counts <200 cells/µL[19]. 
Our findings that men were almost twice as likely as women to enter care with advanced HIV 
disease, and that the prevalence of advanced HIV disease increases with age, add to extensive 
regional data demonstrating the failure of HIV services to adequately engage men and those 
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of working age[15, 18, 20, 21]. Developing strategies to find and engage these groups is therefore 
essential for successful implementation of Treat All programmes. In our cohort only 33% 
(612/1,843) of individuals identified through home-based testing were men, compared to 48% 
(510/1,065) identified through mobile testing, odds ratio 1.8 (95% CI 1.6-2-2; data not shown), 
suggesting that alternative testing models could facilitate engagement of hard-to-reach 
populations in care. Importantly, almost half of individuals presenting with advanced HIV 
disease were already known to be HIV-positive prior to contact with the study team, and 22% 
of these had previously been on ART. This highlights the important and substantial 
contribution of patients who have previously tested HIV-positive, have often started ART, and 
who re-present with low CD4 counts following a period without effective ART, to the overall 
burden of advanced HIV disease, and the need to adapt HIV treatment services to effectively 
retain such patients.  
Clinical staging was of no utility in detecting individuals presenting with CD4 cell counts ≤ 200 
cells/µL, with a sensitivity of 6%. Eighty-two percent of individuals with CD4 ≤200 cells/µL and 
staging data available had WHO stage 1 disease. Baseline CD4 testing therefore remains 
essential to identify individuals with advanced HIV disease and enable implementation of 
differentiated models of care as advocated in WHO guidelines[11]. It is of some concern that 
data from several African countries have shown a marked reduction in the proportion of 
patients undergoing baseline CD4 testing following the introduction of Treat All strategies[22]. 
HIV treatment programmes must ensure retention of CD4 testing capacity to identify and 
appropraiatly manage the population with advanced HIV disease, who continue to make up 
a sizeable proportion of individuals initiating ART. Our data confirm the higher mortality in 
this advanced HIV patient population[12, 14], which may have been underestimated given 
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limitations in our ability to track individuals lost to follow-up, even in a study setting where 
baseline CD4 count was known and enhanced care could be given.  
In conclusion, advanced HIV disease due to late initiation of ART and default or 
disengagement from ART care remains common in the Treat All era in Botswana in the context 
of very high levels of HIV testing and free treatment in a mature HIV program, highlighting 
the need for baseline CD4 testing to identify these at-risk individuals and calling for innovative 
testing, linkage, and treatment strategies to engage and retain harder-to-reach populations 
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Table 1. Patient Characteristics and Associations with Advanced HIV Disease 
(i) Baseline characteristics stratified by baseline CD4 count* 
variable Overall CD4≤200 cells/µL CD4>200 cells/µL p-value† 
Sex  
(% male) 
37.1% (926/2499) 50.9% (219/430) 34.2% (707/2069) <0.001 
Age  
(median, IQR) 
36 (29-44) years 38 (32-46) years 35 (28-44) years <0.001 
New or known HIV  
(% new diagnosis) 
48.5% (1212/2499) 54.2% (233/430) 47.3% (979/2069) 0.010 
WHO stage§ 
(% stage 1 disease) 
88.8% (1586/1787) 82.0% (246/300) 90.1% 1340/1487) <0.001 
Education level§ 
(% secondary) 
62.1% (1551/2497) 60.7% (261/430) 62.4% (1290/2067) 0.516 
Employment§ 
(% employed) 
41.8% (1037/2483) 46.0% (198/430) 40.9% (839/2053) 0.084 
Marital status§ 
(% married) 
23.8% (594/2498) 21.6% (93/430) 24.2% (501/2069) 0.002 
(ii) Associations with Advanced HIV-disease (CD4 ≤ 200 cells/µL) 
Variable Category %CD4≤200 (95%CI) OR (95%CI) aOR (95%CI ‡ 
Sex Female 13.4% (12.3-14.7) base base 
 Male 23.7% (20.5-27.2) 2.0 (1.6-2.5) 1.9 (1.5-2.3) 
Age <25 years 9.1% (8.8-9.3) base base 
 25-34 years 15.0% (12.7-17.7) 1.7 (1.1-2.6) 1.5 (1.0-2.4) 
 >35 years** 20.4% (18.1-22.8) 2.5 (1.7-3.7) 2.2 (1.4-3.2) 
HIV status Known HIV 15.3% (12.8-18.2) base base 
 New HIV 19.2% (16.9-21.7) 1.3 (1.1-1.6) 1.3 (1.0-1.6) 
Testing site 
 
Home 16.0% (13.9-18.3) base base 
Mobile 19.7% (17.7-21.8) 1.3 (1.0-1.6) 1.3 (1.0-1.6) 
Education level Primary 17.9% (14.8-21.4) base base 
Secondary  16.8% (15.6-18.1) 0.9 (0.8-1.2) 1.2 (1.0-1.6) 
Employment Unemployed 16.0% (13.9-18.4) base base 
Employed 19.1% (17.1-21.2) 1.2 (1.0-1.5) 1.0 (0.8-1.3) 
Marital status Married 15.7% (12.9-18.9) base base 
Divorced/widowed 30.5% (24.4-37.4) 2.4 (1.5-3.9) 2.6 (1.6-4.3) 
Single 17.0% (15.7-18.5) 1.1 (0.9-1.4) 1.3 (1.0-1.8) 
(iii) Outcomes stratified by baseline CD4 count 
variable Overall CD4≤200 cells/µL CD4>200 cells/µL p-value† 
In care at 1 year†† 
(% 95%CI) 
97.1% (96.4-97.8) 95.4% (92.9-97.1) 97.6% (96.7-98.2) 0.024 
Viral suppression§§   
at 1 year (% 95%CI) 
91.0% (88.3-93.0) 86.6% (81.8-90.2) 92.1% (89.5-94.0) <0.001 
Mortality - 1 year 
(% 95%CI)§§ 
1.0% (0.6-1.6) 2.1% (1.1-4.1) 0.7% (0.4-1.2) 0.016 
Mortality - overall 
(% 95%CI)‡‡ 
2.3% (1.5-3.5) 4.9% (3.0-7.8) 1.7% (1.0-2.9) <0.001 
IQR: interquartile range; HIV: human immunodeficiency virus; ALT: alanine transaminase; IU: international units; CI: confidence interval; 
OR: odds ratio; aOR: adjusted odds ratio. 
Data are restricted to the 2499 HIV-positive community residents identified who were not taking ART, linked for ART at a BCPP 
intervention community clinic, and had a documented baseline CD4 cell count. During the pre-universal treatment period when point of 
care CD4 testing was taking place in the community, 92% (1843/2000) individuals with CD4 cell counts >200 cells/µL and 92% (317/343) 
with CD4 counts ≤200 cells/µL linked to care at an intervention community clinic (p=0.86). 
*Of the 2499 baseline CD4 cell counts performed, 1,872 (74.9%) were measured using the PIMA CD4 (Alere, Inc.) and 627 (25.1%) using 
the BD FACSCalibur (Beckton Dickinson, Inc.).  
†All p-values are adjusted to account for clustering by community. P-values for comparisons of proportions were derived from a 
hierarchical mixed effects regression model incorporating a random effects term for community. P-values for comparisons of medians 
were derived from ranked testing (F-testing) of Somers’ D parameter estimates accounting for clustering by site (comparable to a 
Kruskall-Wallis test). 
 19 
§Data were incomplete for WHO stage (missing in 712/2499), education (missing in 2/2499), employment (missing in 16/2499), and 
marital status (missing in 1/2499). 
‡ All odds-ratios were adjusted for clustering by community using a hierarchical mixed effects regression model incorporating a random 
effects term for community. Adjusted odds-ratios were derived from multivariable models including age and sex (plus the additional 
exposure variable of interest). The decision to include age and sex in the models was made a priori. 
**There was no significant difference in the prevalence of advanced HIV disease in those aged 35-49 years (21%) and those aged >50 
years (19%). Separate categories for older age groups were not included due to relatively small numbers of elderly indivuduals in the 
study population.  
††Analysis is restricted to the 2,117/2,193 antiretroviral therapy (ART) eligible individuals who initiated ART. P-value derived from a Cox 
Proportional Hazards model adjusted for clustering by community.  
§§All individuals linking more than one year prior to data censoring. 





Table 2. Patient Characteristics and Associations with Very Advanced HIV Disease (CD4 
count ≤100 cells/µL) 
(i) Associations with Very Advanced HIV-disease (CD4 ≤ 100 cells/µL) 
Variable Category %CD4≤100 (95%CI) OR (95%CI) aOR (95%CI § 
Sex Female 3.8% (3.0-4.8) base base 
 Male 7.6% (5.7-10.0) 2.1 (1.4-2.9) 1.9 (1.3-2.7) 
Age <25 years 1.5% (0.6-3.7) base base 
 25-34 years 4.2% (3.2-5.6) 2.9 (1.2-7.5) 2.6 (1.0-6.8) 
 >35 years 6.7% (5.2-8.6) 4.7 (1.9-11.7) 4.1 (1.6-10.1) 
HIV status Known HIV 5.0% (3.6-6.8) base base 
 New HIV 5.4% (4.0-7.5) 1.1 (0.8-1.6) 1.1 (0.7-1.5) 
(ii) Outcomes stratified by baseline CD4 count 
variable Overall CD4≤100 cells/µL CD4>100 cells/µL p-value* 
In care at 1 year‡ 
(% 95%CI) 
97.1% (96.4-97.8) 95.2% (88.2-98.0) 98.2% (97.4-98.9) 0.020 
Viral suppression** 
at 1 year (% 95%CI) 
91.0% (88.3-93.0) 87.4% (79.0-92.8) 91.2% (88.3-93.4) 0.115 
Mortality - 1 year 
(% 95%CI) †† 
1.0% (0.6-1.6) 4.6% (2.0-10.2) 0.8% (0.4-1.4) <0.001 
Mortality - overall 
(% 95%CI) †† 
2.3% (1.5-3.5) 8.5% (4.3-16.0) 1.9% (1.2-3.1) <0.001 
HIV: human immunodeficiency virus; CI: confidence interval; OR: odds ratio; aOR: adjusted odds ratio. 
*All p-values are adjusted to account for clustering by community. P-values for comparisons of proportions were derived from a 
hierarchical mixed effects regression model incorporating a random effects term for community.  
§ All odds-ratios were adjusted for clustering by community using a hierarchical mixed effects regression model incorporating a random 
effects term for community. Adjusted odds-ratios were derived from a multivariable model including age and sex. 
‡Analysis is restricted to the 2,117/2,193 antiretroviral therapy (ART) eligible individuals who initiated ART. P-value derived from a Cox 
Proportional Hazards model adjusted for clustering by community. 96.6% and 95.4% of individuals with CD4 counts >100 cells/µL and 
≤100 cells/µL respectively initiated ART. 
**All individuals linking more than one year prior to data censoring. 






Figure 1 Legend. Advanced HIV disease (baseline CD4 cell count ≤200 cells/µL) in the 
Botswana Combination Prevention Project (BCPP). Panel (A) shows the overall proportion of 
individuals linking to BCPP intervention community clinics with advanced HIV disease; 
430/2499 (17.2%, 95% confidence interval 15.7-18.8%) had a baseline CD4 count ≤200 
cells/µL; 130/2499 (5.2%, 95% confidence interval 4.3-6.3%) had very advanced HIV disease 
(CD4 count ≤100 cells/µL) – see Table 2. Panel (B) shows the proportion of individuals 
presenting with advanced HIV-disease stratified by age and sex. Men were significantly more 
likely than women to present with CD4 cell counts ≤200 cells/µL, p<0.001 in univariable 
analysis and after adjustment for age. Older age was significantly associated with increasing 
odds of presenting with advanced HIV-disease in both men and women, p<0.001 in 
univariable analysis and after adjustment for sex. Panel (C) presents Kaplan Meier curves 
showing retention in HIV-care following linkage to BCPP intervention community clinics, 
stratified by baseline CD4 count, restricted to individuals initiating ART. Patients with baseline 
CD4 cell counts ≤200 cells/µL had significantly higher rates of attrition from care during study 
follow-up (hazards ratio 1.47, 95% confidence interval 1.1-2.1, adjusted for clustering by 
community).  
 
Figure 2 Legend. Retention in HIV-care among patients presenting with CD4 cell counts ≤200 
cells/µL stratified by prior knowledge of HIV status (new or known diagnosis). Kaplan Meier 
curves showing retention in HIV-care following linkage to BCPP intervention community 
clinics, stratified by knowledge of HIV status at study presentation, restricted to individuals 
initiating ART. There was no significant difference between groups (hazards ratio 1.12, 95% 
confidence interval 0.6-2.0, adjusted for clustering by community).  
 
 
